Young child with Doctor

Latest press releases

Wednesday, 30 September 2015
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies –AMAGINE-2 and AMAGINE-3 – demonstrating that treatment with brodalumab resulted in significant clinical improvements in patients with moderate to severe psoriasis and was superior to both placebo and ustekinumab, a leading approved treatment for psoriasis.
Thursday, 24 September 2015
AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib) AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research underpinning its scientific leadership in oncology, at the European Cancer Congress (ECC) 2015 in Vienna, Austria (25-29 September 2015).
Tuesday, 22 September 2015
AstraZeneca to present data demonstrating diversity of its portfolio of innovative formulations and devices at the European Respiratory Society International Congress 2015 AstraZeneca will present 33 abstracts from across the respiratory disease portfolio at the 2015 European Respiratory Society (ERS) meeting in Amsterdam, Netherlands, 26-30 September. Data will include results from AstraZeneca’s growing inhaled portfolio of LAMA/LABA therapies, as well as findings from the company’s biologics pipeline and early science programmes.
Thursday, 17 September 2015
AstraZeneca presents positive pooled analysis demonstrating the effect of dapagliflozin on albuminuria in hypertensive patients with type 2 diabetes Two Phase III clinical trials demonstrate the safety and efficacy profile of dapagliflozin compared to placebo when added to standard of care in patients with hypertension and type 2 diabetes • Post-hoc analysis shows that dapagliflozin in addition to treatment with ACE inhibitors (ACEi) or Angiotensin II Receptor Blockers (ARBs) achieved greater reductions in albuminuria from baseline without increasing serious renal adverse events
Tuesday, 15 September 2015
AstraZeneca announces new tolerability, long-term efficacy and real-world adherence data for exenatide once weekly in patients with type 2 diabetes New pooled data from direct comparative trials indicate upper gastrointestinal adverse events occur more frequently with shorter-acting glucagon-like peptide-1 receptor agonists (GLP-1RA), compared to exenatide once weekly • Real-world evidence trial finds greater adherence to treatment with exenatide once weekly versus liraglutide once daily in patients in Germany initiating GLP-1RA therapy • Combined analysis of DURATION-1, -2, -3 examines three-year efficacy and safety of exenatide once weekly compared to insulin glargine
Friday, 11 September 2015
AstraZeneca to present comprehensive data from its diabetes portfolio and pre-clinical research at EASD 2015 AstraZeneca today announced that 54 abstracts from the company’s research and development in diabetes will be presented at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden, 14-18 September 2015.
Friday, 11 September 2015
AstraZeneca purchases US biologics manufacturing facility to support growing pipeline AstraZeneca today added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc. Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.
Tuesday, 8 September 2015
AstraZeneca to invest £11.5 million in new clinical oncology bioinformatics collaboration with The University of Manchester AstraZeneca and The University of Manchester today announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients. The five-year agreement will see the organisations apply clinical trial bioinformatics to better identify the right cancer treatment for the right patient at the right time.
Friday, 4 September 2015
AstraZeneca to update on leading lung cancer portfolio at WCLC 2015 Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer (WCLC) 2015, beginning this weekend in Denver, Colorado. Presentations will feature 25 abstracts (including 9 oral and 4 late breaker presentations) on the company’s lung cancer pipeline, designed to address the unmet needs of patients with different forms of lung cancer.
Thursday, 3 September 2015
US FDA approves expanded indication for BRILINTA to include long-term use in patients with a history of heart attack AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved BRILINTA® (ticagrelor) tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year. With this expanded indication, BRILINTA is now approved to reduce the rate of cardiovascular death, myocardial infarction (MI, also known as heart attack) and stroke in patients with acute coronary syndrome (ACS) or a history of MI.